• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA• Launch preparations are underway to bring the second approved golimumab biosimilar to patients acro...
View DetailsGuangzhou, China– June 2 , 2024 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, will present aposter at the 2024 ASCO Annual Meeting entitled “Phase 1 s...
Bio-Theraand STADA have reached an exclusive commercialization and license agreement forBAT2506, a biosimilar candidate to Simponi® (golimumab) Bio-Thera will maintain responsibility fordevelopment, manufacturing, and supply of BAT2506 STADA willhav...
GUANGZHOU, China - Bio-Thera Solutions (688177.SH), a commercial-stage biopharmaceutical company developinginnovative therapies and biosimilars, announced that its partner, Biogen Inc.(Nasdaq: BIIB) officially launched TOFIDENCE (tocilizumab-bavi) in...
